

Inotropic and Antiarrhythmic Transmural Actions of Ranolazine in a Cellular Model of Type 3 Long QT Syndrome

Victor Martins Miranda,¹ Samuel Santos Beserra,¹ Danilo Roman-Campos¹

Universidade Federal de São Paulo, Departamento de Biofísica, Edifício de Ciências Biomédicas,¹ São Paulo, SP - Brazil

Abstract

Ranolazine (RANO) prevents cardiac arrhythmia by blocking the late sodium current (I_{NaL}). A transmural gradient of Nav1.5 is found in the left ventricular wall of the heart. Thus, we investigated the effects of RANO in healthy cardiomyocytes and in a cellular model of type 3 long QT syndrome (LQT3). We used isolated endocardium (ENDO) and epicardium (EPI) cells and a video edge detection system and fluorescence microscopy to monitor calcium transients. RANO (0.1, 1, 10 and 30 μ M, at 25°C) at a range of pacing frequencies showed a minor impact on both cell types, but RANO at 30 μ M and 35°C for ENDO cells attenuated sarcomere shortening by ~21%. Next, to mimic LQT3, we exposed ENDO and EPI cells to anemone toxin II (ATX-II), which augments I_{NaL} . Cellular arrhythmias induced by ATX-II were abrogated by RANO (30 μ M) at 35°C. Based on our results we can conclude that RANO has a minor impact on sarcomere shortening of healthy ENDO and EPI cells and it abrogates arrhythmias induced by I_{NaL} to a similar level in ENDO and EPI cells.

Introduction

Arrhythmia in cardiovascular diseases is one of the leading causes of death worldwide.¹ The antiarrhythmic action of RANO is attributed to reduction in the slow inactivating component of cardiac inward current through Nav1.5, known as the late sodium current (I_{NaL}).² Despite major advances in the understanding of molecular mechanisms underlying RANO action, whether RANO exhibits a transmural action in heart muscle cells remains uncertain. Therefore, in the present study our hypothesis is that RANO has transmural action on healthy field-stimulated endocardium (ENDO) and epicardium (EPI) cells and also on arrhythmias and calcium disturbance induced by anemone toxin II (ATX-II),³ which increases I_{NaL} and mimics several aspects of type 3 long QT syndrome (LQT3), a diseased linked to increased I_{NaL} in heart cells.²

Keywords

Arrhythmias, Type 3 Long QT Syndrome, ATX-II, Late Sodium current, Ranolazine, Contraction.

Mailing Address: Danilo Roman Campos •

Universidade Federal de São Paulo – Biofísica - Rua Botucatu, 862.

Postal Code 04023-062, São Paulo, SP – Brazil

E-mail: drcbio@gmail.com

Manuscript received April 03, 2019, revised manuscript August 19, 2019, accepted September 10, 2019

Methods

Animals

Male Wistar rats (160–250 g; 5–7-week old) were used in the experiments. All experimental procedures were performed in accordance with institutional guidelines, and the study was approved by the local ethical review committee. Cardiomyocytes were isolated as previously described.⁴

Sarcomere shortening and calcium transient

Experiments were conducted as previously described by our group.⁵ Cells were perfused with RANO (Alomone, Israel) at 0.1, 1, 10, or 30 μ M from a 10 mM stock solution. Data were normalized as the function of sarcomere contraction before RANO exposure. To access the antiarrhythmic effect of RANO following exposure to 6 nM ATX-II (Alomone, Israel), the times to 90% sarcomere relaxation (T90R) and calcium reuptake (T90Ca²⁺) were recorded as arrhythmic indexes. In addition, 10 mM tetrodotoxin (TTX) (Alomone, Israel) was used to confirm that the observed phenotype was indeed due to I_{NaL} .

Statistical analysis

All results are expressed as mean \pm standard error of the mean. Significant differences were determined using two-sample t-test or one-way ANOVA with repeated measures, followed by Tukey's post hoc test. $P < 0.05$ was considered significant. Cardiomyocytes from at least two distinct hearts were used in each experiment.

Results and discussion

Previous studies have shown that healthy cardiomyocytes exhibit I_{NaL} .⁶ Moreover, a gradient of sodium current has been recorded in the left ventricular wall, and it has been reported to be larger in ENDO cells than in EPI cells.⁷ Thus, we hypothesized that ENDO cells present larger I_{NaL} than EPI cells. Since I_{NaL} modulates $[Ca^{2+}]_i$ in cardiomyocytes,⁸ RANO would be able to attenuate contraction in both cell groups, although with greater potency in ENDO cells than in EPI cells. To test this hypothesis, cells were perfused at 25°C with RANO; however, RANO could not attenuate sarcomere shortening in ENDO and EPI cardiomyocytes (Figures 1 A and C). A similar trend was observed when cardiomyocytes were exposed to 30 μ M RANO and paced at 0.2 Hz. When ENDO and EPI cells were exposed to 30 μ M RANO and paced at 0.2 Hz using a superfusion solution at 35°C, cell shortening was attenuated in ENDO cells by ~21% ($p < 0.05$) but not in EPI cells (Figures 1B and D). Thus, corroborating the previous findings, our results suggest that healthy ENDO cells indeed

Brief Communication

present larger I_{NaL} than EPI cells. However, it is also important to note that 30 μM RANO could also block L-type calcium current in cardiomyocytes.⁹

To better understand the mechanism underlying sarcomere shortening induced by RANO, subsequent experiments were performed at 35°C. Cardiomyocytes were loaded with Fura 2-AM to monitor calcium oscillation during cell contraction, and cells were exposed to ATX-II to increase I_{NaL} and induce an LQT3 phenotype³ (Figure 2). ENDO (Figures 2A, B and C) and EPI (Figures 2D, E and F) cells exposed to ATX-II showed clear calcium disturbances and simultaneous mechanical arrhythmias. RANO (30 μM) strongly attenuated the arrhythmic phenotype induced by ATX-II in both cell groups to a similar extent. To confirm that the arrhythmic phenotype observed in our experiments was truly attributed to I_{NaL} cells were exposed to 6 nM ATX-II [Figure 2A (iv) and Figure 2D (iv)], following exposure to 10 μM TTX and 6 nM ATX-II [Figure 2A (v) and Fig 2D (v)]. The results confirmed that the observed arrhythmic phenotype occurred due to I_{NaL} augmentation. Despite the fact that rat ENDO cells present larger sodium currents than EPI

cells,^{7,10} the arrhythmic phenotype induced by ATX-II and the extent of antiarrhythmic effects of RANO were similar in both cell groups.

Interestingly, the therapeutic concentration range of RANO is 1–10 μM .¹¹ The apparent discrepancy in RANO potency may be explained by the fact that ATX-II at doses of 1–10 nM induces larger I_{NaL} in cardiomyocytes than that observed in cardiovascular disease.^{3,6}

Conclusion

RANO exerted a minor impact on sarcomere shortening of healthy cardiomyocytes and abrogated arrhythmias induced by I_{NaL} to a similar extent in ENDO and EPI cells.

Author contributions

Conception and design of the research and Writing of the manuscript: Campos DR; Acquisition of data: Miranda VM, Beserra SS; Analysis and interpretation of the data and Statistical analysis: Miranda VM, Campos DR.




Figure 1 – Inotropic effect of ranolazine (RANO) on sarcomere shortening of ENDO and EPI cardiomyocytes. Representative sarcomere shortening recordings before (black (25°C) and blue (35°C)) and after (light gray (25°C) and red (35°C)) exposure of ENDO (left) and EPI (right) cardiomyocyte to RANO ((A) 10 and (B) 30 μM). Inotropic effect of 0.1, 1, and 10 μM RANO (C) and 30 μM (D) on sarcomere shortening (upper bars); Normalized time to 50% sarcomere contraction (T50c) (middle bars) and; normalized time to 50% of sarcomere relaxation (T50r) (bottom bars). Hatched bars represent EPI cells ($n = 3-6$ cells/concentration). * $p < 0.05$ comparing before and after RANO exposure.




Figure 2 – Action of ranolazine (RANO) in ENDO and EPI cardiomyocytes exposed to ATX-II and paced at 0.2 Hz. Representative traces of calcium transients (upper traces) and cardiomyocyte sarcomere shortening (lower traces) following exposure to Tyrode's solution (i), 6 nM ATX-II (ii), 6 nM ATX-II + 30 μM RANO (iii), 6 nM ATX-II (iv), and 6 nM ATX-II + 10 μM TTX (v) in ENDO (A) and EPI (D) cells. Time to 90% of Ca²⁺ reuptake in ENDO (n = 8 cells) (B) and EPI (n = 6 cells) (E). Time to 90% sarcomere relaxation in ENDO (C) and EPI (F) cells. * p < 0.05 compared to the ATX-II group.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Sources of Funding

This study was funded by FAPESP nº 2014/09861-1.

Study Association

This article is part of the thesis of master submitted by Victor Martins Miranda, from Universidade Federal de São Paulo.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the CEUA UNIFESP under the protocol number 2435/70816. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013.

Erratum

In the Brief Communication "Inotropic and Antiarrhythmic Transmural Actions of Ranolazine in a Cellular Model of Type 3 Long QT Syndrome", pages 732-735, by authors Victor Martins Miranda, Samuel Santos Beserra, Danilo Roman Campos, consider Danilo Roman-Campos as the correct form for the name of the author Danilo Roman Campos.

References

1. Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death. *Circulation*. 2012;125(4):620-37.
2. Bohnen MS, Peng C, Robey SH, Terrenoire C, Iyer V, Sampson KJ, et al. Molecular pathophysiology of congenital long QT syndrome. *Physiol Rev*. 2017;97(1):89-134.
3. Clark RB, Giles WR. Current-voltage relationship for late Na(+) current in adult rat ventricular myocytes. *Curr Top Membr*. 2016;78:451-78.
4. Santos-Miranda A, Cruz JS, Roman-Campos D: Electrical properties of isolated cardiomyocytes in a rat model of thiamine deficiency. *Arq Bras Cardiol*. 2015;104(3):242-5.
5. Santos MS, Oliveira ED, Santos-Miranda A, Cruz JS, Gondim ANS, Menezes-Filho JER, et al. Dissection of the effects of quercetin on mouse myocardium. *Basic Clin Pharmacol Toxicol*. 2017;120(6):550-9.
6. Iyer V, Roman-Campos D, Sampson KJ, Kang G, Fishman GI, Kass RS. Purkinje cells as sources of arrhythmias in long QT syndrome type 3. *Sci Rep*. 2015 Aug 20;5:13287.
7. Rosati B, Grau F, McKinnon D. Regional variation in mRNA transcript abundance within the ventricular wall. *J Mol Cell Cardiol*. 2006;40(2):295-302.
8. Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS: Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. *J Mol Cell Cardiol*. 2006;41(6):1031-8.
9. Allen TJ, Chapman RA. Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. *Br J Pharmacol*. 1996;118(2):249-54.
10. Honen BN, Saint DA: Heterogeneity of the properties of INa in epicardial and endocardial cells of rat ventricle. *Clin Exp Pharmacol Physiol*. 2002;29(3):161-6.
11. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. *J Am Coll Cardiol*. 2004;43(8):1375-82.



This is an open-access article distributed under the terms of the Creative Commons Attribution License